Name: Cereno Scientific discusses phase IIa results for CS1
Uploaded: 2024-10-03T08:45:28+02:00
Channel: Sonja Schwarzenberger
Description: The trial was made with the company’s lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension.See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific:

Cereno Scientific discusses phase IIa results for CS1

3 October, 2024

Cereno’s CEO on being granted “Compassionate Use”

6 February, 2024

Tag: Cereno Sten R Sörensen

Cereno Scientific discusses phase IIa results for CS1

Cereno’s CEO on being granted “Compassionate Use”